Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

An anti-sclerostin and sclerostin technology, applied in the direction of antibody medical components, chemical instruments and methods, anti-growth factor immunoglobulin, etc., can solve problems such as alveolar bone defects

Active Publication Date: 2014-09-10
AMGEN INC +1
View PDF34 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, alveolar bone may become defective due to perforation caused by surgical treatment or apical lesions of progressive caries

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
  • Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
  • Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0139] This example describes different cell-based neutralization assays suitable for characterizing the neutralizing activity of anti-sclerostin antibodies.

[0140] MC3T3 Cell-Based Mineralization Assay - MC3T3-E1-BF cells were induced to differentiate using ascorbic acid and B-glycerophosphate, resulting in mineral deposition. An exemplary screening protocol in a 96-well format involved seeding cells on day 1, followed by 7 media changes over a 12-day period, with most mineral deposition occurring within the last 18 hours. The exact timing and extent of mineral deposition can vary depending in part on the particular serum lot used. Control experiments will allow these variables to be taken into account, as is generally known in the art of cell culture experimentation. For statistical analysis (using MS Excel and JMP), one-way ANOVA followed by Dunnett's comparison was used sequentially to determine differences between groups. Group means of data sets were considered signi...

Embodiment 2

[0155]The following examples illustrate the ability of a sclerostin inhibitor, anti-sclerostin monoclonal antibody (Scl-Ab), to enhance alveolar bone repair in a rat model of periodontal disease.

[0156] Rat periodontitis model: Experimental periodontal disease was induced in rats by ligation placement as previously described (Jin Q et al., 2007. J Periodontol 78:1300-1308; Graves, DT et al., 2008. J Clin Periodontol 35:89-105; the disclosure of which is incorporated herein by reference in its entirety). Briefly, male Sprague Dawley rats (approximately 300-350 g body weight, Harlan Laboratory, IN) were anesthetized with ketamine and thiazoline (83 / 17 ratio). A cotton suture (3.0) was then secured around the neck portion of the molar on one side of the mandible (just above the gum) to allow normal chewing. Assess the ligature three times a week, move the tip gently into the crevice to ensure subgingival placement, and replace if necessary.

[0157] Microcomputed tomography (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to view more

Abstract

The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to US Provisional Application No. 61 / 580,964, filed December 28, 2011. The disclosure of said priority application is incorporated herein by reference in its entirety. [0003] invention technical field [0004] The present invention relates generally to methods of treating alveolar bone loss using sclerostin inhibitors. [0005] Incorporation of material submitted electronically [0006] Incorporated by reference in its entirety is the computer readable nucleotide / amino acid sequence listing filed herewith and identified as follows: ASCII (text) filename "46570_SeqListing.txt", 805,989 bytes, December 7, 2012 Said to create. [0007] incorporated by reference [0008] The following applications are hereby incorporated by reference in their entirety: U.S. Patent Application No. 11 / 410,540, filed April 25, 2006, which claims U.S. Provisional Patent Application No. 60 / 792,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/22
CPCA61K39/3955C07K16/22C07K2317/76A61K45/06C07K16/18A61K2039/505A61K2039/545C07K2317/92A61P1/02A61P19/00A61P19/08
Inventor 柯华珠刘敏W·V·格兰诺拜尔
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap